Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis

Marco Gattorno, Paolo Picco, Antonella Buoncompagni, Franca Stalla, Paola Facchetti, Maria Pia Sormani, Vito Pistoia

Abstract

Objective—To determine the expression of tumour necrosis factor α (TNFα) and its soluble receptors (p55 and p75) in the sera and synovial fluid of patients with juvenile chronic arthritis (JCA), and their correlation with disease activity parameters.

Methods—Ninety-eight sera from 45 patients with JCA (14 systemic, 12 polyarticular, 19 pauciarticular), 20 sera from age-matched healthy controls, and five synovial fluids from five antinuclear antibody (ANA) positive pauciarticular JCA patients were tested for the presence of TNFα, soluble TNF receptors p55 and p75 (sTNFRp55, sTNFRp75), and interleukin-6 (IL-6) by an enzyme amplified sensitivity immunoassay. Physician global estimate of disease activity, weekly fever score and joint score, C reactive protein (CRP), erythrocyte sedimentation rate (ESR), and haemoglobin concentration were evaluated as parameters of disease activity. The expression of p55 and p75 on peripheral mononuclear cells (MNCs) from five patients with systemic JCA and synovial MNCs from five ANA positive patients with pauciarticular JCA was evaluated by flow cytometry.

Results—TNFα serum concentrations did not differ significantly between the patients with active JCA and the control group. No correlation was found between TNFα and parameters of disease activity, but both p55 and p75 showed a significant positive correlation with the physician global estimate of disease activity (p < 0.001), ESR (p < 0.001), CRP (p < 0.001), and serum concentrations of IL-6 (p < 0.001). Serum concentrations of haemoglobin correlated inversely with the concentrations of p55 and p75 (p < 0.001). Synovial lymphocytes selectively expressed the p75 surface receptor.

Conclusions—sTNFRp55 and sTNFRp75 each represent a sensitive marker of disease activity in JCA. Their increased expression in biological fluids may support the hypothesis that TNFα has a role in the pathogenesis of rheumatoid arthritis (RA). TNFα and interleukin-1 (IL-1) are able to stimulate bone resorption in vitro, to induce the expression of adhesion molecules including intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, and to stimulate synovial cell production of prostaglandin E2 and collagenase.

In the collagen induced arthritis model in DBA/1 mice, treatment with monoclonal TNFα antibodies reduced joint swelling and cartilage and bone erosion. A transgenic mouse expressing human TNFα developed a symmetric polyarthritis characterised by cartilage destruction, bone erosion, and leucocyte infiltration. Finally, in a recent double blind trial, the administration of TNFα chimeric monoclonal antibodies has been shown to be effective and safe in the short term treatment of patients with RA.

TNFα has been detected in sera and synovial fluids and at the cartilage-pannus junction in patients with RA. The few studies conducted on the expression of cytokines in the biological fluids of patients with juvenile chronic arthritis (JCA) have shown that, unlike other proinflammatory cytokines (particularly IL-1 and IL-6), TNFα is found in sera and synovial fluids in small amounts.

The soluble TNFα receptors p55 and p75 (sTNFRp55, sTNFRp75) neutralise the biological activity of TNFα in the fluid phase, and their shedding from the cell surface is believed to be related to TNFα production. In this study, we have investigated the reciprocal relationship between TNFα and these soluble receptors in sera from 45 patients with JCA, and evaluated their correlation with parameters of disease activity and with the serum concentrations of interleukin-6 (IL-6), a cytokine that is detected in high concentrations during the acute phase of JCA.

Patients and methods

The study was approved by the Ethics Committee of our Institute. Forty-five patients with JCA (23 men, 22 women) were included in the study. Twenty age matched healthy subjects attending our clinic for a follow up visit after an acute self limiting inflammatory or infectious disease were included as controls after the parents gave their informed consent. Any subject giving a history of inflammatory or infectious disease in the four weeks preceding

Clinical characteristics of patients and treatment at the time of the study

<table>
<thead>
<tr>
<th></th>
<th>Systemic (n = 14)</th>
<th>Polyarticular (n = 12)</th>
<th>Pauciarticular (n = 19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>4-2 (1-2-12)</td>
<td>9-3 (6-2-16)</td>
<td>5-6 (1-1-15-7)</td>
</tr>
<tr>
<td>Disease duration (yr)</td>
<td>1-4 (0-2-6)</td>
<td>3-8 (0-9-4-6)</td>
<td>1-2 (0-2-5-9)</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>9/5</td>
<td>5/7</td>
<td>9/10</td>
</tr>
<tr>
<td>High activity (47 sera)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAID (%)</td>
<td>15-5</td>
<td>61-3</td>
<td>54-8</td>
</tr>
<tr>
<td>NSAID + GC (%)</td>
<td>37-5</td>
<td>14-3</td>
<td>11-7</td>
</tr>
<tr>
<td>NSAID + SMARD (%)</td>
<td>24-2</td>
<td>35-4</td>
<td>9-2</td>
</tr>
<tr>
<td>No treatment (%)</td>
<td>12-8</td>
<td></td>
<td>25-3</td>
</tr>
<tr>
<td>Global estimation score</td>
<td>3-9 (0-5)</td>
<td>3-4 (0-5)</td>
<td>3-3 (0-4)</td>
</tr>
<tr>
<td>Fever score</td>
<td>2-8 (0-3)</td>
<td>1-1 (1-2)</td>
<td>2-8 (0-7)</td>
</tr>
<tr>
<td>Joint score</td>
<td>1-0 (1-2)</td>
<td>0-6 (0-6)</td>
<td>0-9 (0-9)</td>
</tr>
<tr>
<td>Low activity (51 sera)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAID (%)</td>
<td>21-3</td>
<td>42-6</td>
<td>57-8</td>
</tr>
<tr>
<td>NSAID + GC (%)</td>
<td>49-6</td>
<td>28-3</td>
<td>20-1</td>
</tr>
<tr>
<td>NSAID + SMARD (%)</td>
<td>29-1</td>
<td>40-1</td>
<td>7-5</td>
</tr>
<tr>
<td>Off treatment (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global estimation score</td>
<td>1-1 (0-9)</td>
<td>0-86 (0-9)</td>
<td>0-7 (0-9)</td>
</tr>
<tr>
<td>Fever score</td>
<td>0-6 (0-6)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Joint score</td>
<td>0-2 (0-2)</td>
<td>0-7 (0-5)</td>
<td>0-8 (0-4)</td>
</tr>
</tbody>
</table>

Values are mean (range) or mean (SD), where relevant.
NSAID = Non-steroidal anti-inflammatory drugs; GC = glucocorticoids; SMARD = slow modifying antirheumatic drugs; ND = not done.

the examination was excluded. The mean age of the JCA patients was 6-3 years (range 1-16-3 years); 14 of them were affected with systemic JCA, 12 with polyarticular JCA, and 19 with pauciarticular JCA according to the European League Against Rheumatism criteria. The pauciarticular group included one antinuclear antibody (ANA) positive patients only; neither spondyloarthropathy nor psoriatic arthritis patients were considered. Among the 12 polyarticular JCA patients, four were ANA positive and one was IgM rheumatoid factor positive. The table shows the main characteristics of the patients and the treatment they were receiving at the time of the study. Clinical parameters for disease activity included physician global estimate of disease activity, weekly fever score (systemic JCA), and joint score (systemic, poly-, and pauciarticular JCA). C reactive protein (CRP), haemoglobin concentration, and erythrocyte sedimentation rate (ESR) were evaluated as laboratory parameters of disease activity.

Physician global estimate of disease activity was scored from 0 to 4.11 Fever was scored as follows: 0 = absence of fever flares in the week before examination; 1 = 1-3 weekly flares; 2 = 4-6 weekly flares; 3 = daily flares. Joint involvement was graded from 0 to 3 according to the number of painful joints, number of swollen joints, and range of motion: 0 = absence of any articular involvement; 1 (mild) = fewer than three painful or swollen joints, and a reduction in range of motion of at least a single joint not exceeding 25%; 2 (moderate) = 4-6 joints involved or a range of motion between 25% and 50% in at least a single joint; 3 (severe) was assigned to patients who displayed inflammatory involvement of seven or more joints or a reduction in range of motion greater than 50% in at least one joint. Although there are no published data on the usefulness of these clinical parameters, fever and joint scores seemed to correlate well with disease activity in this study.

High disease activity was assessed as physician global estimate of disease activity scored 3 or 4, fever or joint scores 2 or 3, and ESR or CRP values increased above the normal range. Low disease activity was defined by physician global estimate of disease activity scores of 0-2, fever and joint score 0 or 1, and ESR and CRP values within the normal range. Ninety eight sera from 45 patients with JCA were tested retrospectively for the presence of TNFα, sTNFαRp55, sTNFαRp75, and IL-6, at different times during their disease: on three occasions in seven patients, on two occasions in 32, and on a single occasion in six patients. The corresponding disease activity scores were obtained from the patients’ case notes. Aliquots of sera were frozen at −80°C until assayed by enzyme amplified sensitivity immunoassay (EASIA) kits from Medigenix Diagnostic (Pleurus, Belgium), according to the manufacturer’s instructions. These tests are based on an oligoclonal system in which several monoclonal antibodies (MAbs) directed against distinct epitopes of TNFα, IL-6, sTNFαRp55, and sTNFαRp75 are used. The kits for TNFα and IL-6 assays have been shown to detect both free and soluble receptor bound cytokines.12 Briefly, the capture antibodies are attached to the lower and inner surface of the plastic well and standards or samples are added to the well. After incubation, the unbound excess of antigen is removed by washing. The secreted antibody, horseradish peroxidase labelled antibody, is added, and after incubation and washing, the microtitre plate is washed again to remove unbound enzyme labelled antibodies.

Evaluation of the expression of sTNFαRp55 and sTNFαRp75 on mononuclear cells (MNCs) was performed by flow cytometry using MAbs htr-9 (for p55) and utr-1 (for p75),13 kindly provided by Dr Manfred Brockhaus (Hoffman-La Roche, Basel). Staining for both receptors was by indirect immunofluorescence before and after acid stripping of surface TNFα binding to the receptor antibody cells were resuspended in a 'stripping solution' (sodium chloride 125 mmol/l and glycine 25 mmol/l at pH 2.8) for four minutes at 4°C. Cells were washed in RPMI medium supplemented with 10% fetal calf serum (both from Seromed Biochrom, Berlin, Germany), stained with TNFαR MAbs, and analysed by flow cytometry using a FACSScan (Becton-Dickinson, Mountain View, California, USA) with the gate set on either lymphocytes or monocytes-macrophages. Under the experimental conditions used, fewer than 3% of the lymphocyte cells detected by the anti-CD3 antibody were present within the lymphocytes gate. Likewise, CD3 cells were fewer than 2% in the gated monocyte-macrophage population.

In a preliminary series of experiments, the mean TNFα, sTNFαRp55, and sTNFαRp75 concentrations were tested in synovial fluid from five pauciarticular, ANA positive JCA patients.

STATISTICAL ANALYSIS
Quantitative differences between patient groups were assessed by non-parametric statistical analysis using the Mann-Whitney U test.
Correlations among sTNFαRs, parameters of
disease activity, TNFα, and IL-6 were determined by linear correlation and Spearman’s rank test.

**Results**

Mean serum concentrations of TNFα were greater in the JCA patients with high disease activity (31 (SD 44.1) pg/ml) than in those with low disease activity (24 (35) pg/ml) and those in the control group (15.5 (6-9) pg/ml), but there were no statistically significant differences between the three groups. Similarly, there was no significant difference in TNFα serum concentration among the JCA subtypes. There was no correlation between TNFα and disease activity parameters.

Serum concentrations of IL-6 were significantly increased in patients with active JCA (60.5 (40-9) pg/ml) compared with those with inactive disease (21.5 (7-4) pg/ml) (p < 0.001) or controls (25 (9-5) pg/ml) (p < 0.001), but the concentrations were comparable among the patients with different subtypes of JCA (data not shown).

Concentrations of both sTNFαRp55 and sTNFαRp75 correlated positively with physician global estimate of disease activity (r = 0.62, p < 0.001; r = 0.67, p < 0.001, respectively).

Figure 1 shows the correlations between sTNFαRp55 and sTNFαRp75 serum concentrations and parameters of disease activity for all the patients with JCA. A positive correlation was found with both ESR (fig 1) and CRP (r = 0.54, p < 0.001; r = 0.43, p < 0.001 for p55 and p75, respectively), and between each sTNFαR and serum concentrations of IL-6 (fig 1), but haemoglobin concentration was inversely correlated with the serum concentrations of the sTNFαRs (fig 1).

Figure 2 shows the relationship between the serum concentrations of sTNFαRp55 or p75 and disease activity in patients with systemic, polyarticular, or pauciarticular JCA. A significant difference was detected for both sTNFαRp55 and sTNFαRp75 between patients with the active and inactive systemic and polyarticular disease subtypes, and between the same patients and controls (p < 0.001), but a different pattern was observed for pauciarticular JCA: the serum concentrations of sTNFαRp75 were significantly greater in patients with active disease than in those with inactive disease or in controls (p < 0.001),

![Graphs showing the correlations between TNF activity and disease parameters.](http://ard.bmj.com/)

**Figure 1.** Linear correlations between serum concentrations of soluble tumour necrosis factor α receptors p55 (left) and p75 (right), and erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6) concentration, and haemoglobin (Hb) concentration.
whereas for sTNFαR55 a significant difference was detected only between patients with active disease and controls (p = 0.02) (fig 2).

The mean TNFα, sTNFαR55, and sTNFαR75 concentrations in synovial fluid from five pauciarticular, ANA positive JCA patients were 31 (15-5) pg/ml, 10-5 (12-3) ng/ml, and 19 (10-3) ng/ml, respectively. It is of note that, in spite of the variability in individual patients’ results, the expression of both sTNFαRs in synovial fluid was greater than was detected concurrently in sera, with a trend for concentrations of sTNFαR75 to be consistently greater than those of the p55 receptors.

Peripheral blood MNCs from five patients with active systemic JCA and synovial MNCs from five patients with pauciarticular JCA were tested by flow cytometry either before or after stripping to remove membrane bound TNFα.

No surface sTNFαR55 or p75 was detected on the peripheral blood lymphocytes or monocytes of the patients with active systemic JCA, and no surface sTNFαR55 was observed on synovial MNC in the pauciarticular patients. In contrast, sTNFαR75 was expressed on the synovial lymphocytes of four of the five patients with pauciarticular JCA, in particular after stripping: 7% before stripping v 20% after stripping; 4% before v 13% after; 8% before v 14% after; 11% before v 20% after, respectively. No expression of sTNFαR75 was detected on synovial fluid macrophages, either before or after stripping.

Discussion
In this study, we have investigated the concentrations of TNFα, sTNFαR55, and sTNFαR75 in sera from patients with systemic, pauciarticular, or polyarticular JCA.

Because of the wide interindividual variability, serum concentrations of TNFα in patients with JCA did not show any significant difference from normal controls. In particular, as reported previously, no correlation was found between serum concentrations of TNFα and parameters of disease activity. The implications of these findings are difficult to interpret, particularly as cytokines exert their effects mainly at sites of inflammation.15

It is well known that both sTNFαRs are the shed forms of truncated cell membrane p55 and p75 TNFα receptors, produced by proteolytic cleavage. As TNFα itself is one of the best inducers of sTNFαR expression,16 study of the latter molecules would seem to be a useful indirect indicator of TNFα production. In our study, the concentrations of both p55 and p75 serum sTNFαRs were found to be significantly increased, especially during the active phase of JCA. Furthermore, the clinical usefulness of sTNFαR assays was demonstrated by the positive correlation of serum sTNFαR55 and p75 concentrations with the physician global estimate of disease activity, and with CRP, ESR, and serum concentrations of IL-6.

In a recent paper, the serum concentration of sTNFαR55 was found to be increased in patients with JCA, irrespective of the disease subtype, and the concentrations of the receptor correlated with some indicators of JCA activity.14 However, sTNFαR75, which we found in the present study to be a sensitive, and sometimes more reliable, marker of JCA activity (pauciarticular subtype) was not studied. In addition, as already reported in RA,17 the concentration of sTNFαR75 in patient sera was significantly greater than that of sTNFαR55.

Our preliminary studies on synovial fluids demonstrated a greater concentration of both TNFα and sTNFαRs compared with those concomitantly detected in sera, greater concentrations of sTNFαR75 compared with p55, and a selective expression of surface TNFαR55 on synovial fluid lymphocytes. All of these findings are in agreement with previous observations in patients with RA.17 18

A possible clue to the interpretation of the greater expression of sTNFαR75 both in biological fluids and on the lymphocyte surface may come from studies showing that interaction of TNFα with lymphoid or myeloid cells causes a partial but selective shedding of membrane sTNFαR75 in the fluid phase.19 20 Such a model, however, does not explain why increased concentrations of sTNFαR55 were
detected in sera from most patients with JCA; it is conceivable that cells other than lymphocytes may be responsible for p55 shedding at the sites of inflammation, as possibly suggested by the expression of surface TNFαRp55 (in addition to p75) in RA synovium.21

In conclusion, the increased expression of sTNFαRp55 and p75 in the biological fluids of patients with JCA may represent indirect evidence for the role of TNFα in the pathogenesis of JCA, despite the variable serum concentrations of this cytokine.

We wish to thank Dr M Brockhaus for kindly providing us with his TNFαR monoclonal antibodies, Dr E Franchini for their collaboration, and Drs M Ponzoni and P Montaldo for their helpful suggestions.

Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis.

M Gattorno, P Picco, A Buoncompagni, F Stalla, P Facchetti, M P Sormani and V Pistoia

doi: 10.1136/ard.55.4.243

Updated information and services can be found at:
http://ard.bmj.com/content/55/4/243

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/